Case-Based Roundtable Meetings Spotlight May 2021: Solid Tumors

One year following treatment with androgen deprivation therapy, a 57-year-old patients with nonmetastatic castration-resistant prostate cancer presented again with a PSA doubling time of 8.6 months and was still nonmetastatic.

The CheckMate 9ER study compared nivolumab plus cabozantinib with sunitinib and found that as disease becomes less favorable by prognostic risk. Promise has now been shown for this population with the combination of lenvatinib and everolimus.

The case of a 75-year-old man with stage T2N0M0 prostate cancer was the topic of discussion between 8 oncologists, a physicians assistant, and a nurse practitioner during a recent Targeted Oncology Case-Based Roundtable event moderated by Daniel Landau, MD.

During a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, discussed the results of cabazitaxel as a later-line treatment for patients with metastatic castration-resistant prostate cancer.

Steven I. Sherman, MD, FACE, moderated a Targeted Oncology Case-Based Roundtable event during which experts discussed the characteristics of patients with radioiodine-refractory differentiated thyroid cancer and how to consider them when selecting treatment.

During a virtual Targeted Oncology Case-Based Roundtable event, Timothy F. Burns, MD, PHD, discussed the treatment of non–small cell lung cancer based on clinical trial research.

Treatment options are available for patients with late-stage gastric cancer in the early- to late-line settings.

The treatment landscape for gastric cancer is evolving. The use of biomarkers and implementation of testing to improve outcome later on in the course of treatment are being more important.

During a Targeted Oncology Case-Based Roundtable event, Evan Y. Yu, MD leads a discussion on hereditary germline mutations impact on prostate-cancer risk.

Chemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.

The PACIFIC study included patients with good performance status and unresectable, stage III NSCLC who did not progress after definitive platinum-based chemotherapy with concurrent radiation.

Eleni Efstathiou, MD, PhD, discussed clinical trials which support the use of certain treatment regimen for patients with nonmetastatic castration-resistant prostate cancer.